lbs; p¼.52) nor GWG within/below guidelines (50.8% vs 47.7%; p¼.73) differed between the intervention group and usual care. Results were unchanged when only obese women were included in the analysis. There was a trend towards fewer cases of large for gestational age neonates in the intervention group (11% vs 28%; p¼.07) among obese women. CONCLUSION: An intensive behavioral intervention did not improve adherence to GWG guidelines in overweight and obese gravidas. These data suggest that antenatal modifications to GWG may be limited and highlights the importance of prepregnancy weight loss. Novel approaches are needed to optimize GWG in overweight and obese women.
OBJECTIVE:
Response to medications and pregnancy outcomes vary in women with gestational diabetes mellitus (GDM). We sought to describe subtypes of GDM based on mechanisms of hyperglycemia and assess the frequency of adverse pregnancy outcomes. STUDY DESIGN: We performed a prospective cohort study of 111 pregnant women with singleton gestation at 24-30 weeks' undergoing oral glucose tolerance testing. We estimated insulin sensitivity and secretion using the Matsuda and Stumvoll index, respectively. Low insulin sensitivity or secretion were defined using values below the 25 th percentile as established in women with normal glucose tolerance. Women with GDM (n¼33) were divided into the subtypes of insulin resistance, insulin secretion deficiency, or a combination of both. RESULTS: Predominant insulin resistance occurred in 45%, predominant insulin secretion deficiency in 33%, and combined insulin resistance and insulin secretion deficiency defects in 21% of women with GDM. Relative to women with normal glucose tolerance, those with combined defects had higher pre-pregnancy BMI (36.3 AE 12.8 vs.28.5 AE 6.4, p¼ 0.01) and fasting glucose (106.7 AE 23.5 vs. 82.9 AE 9.7, p<0.0001), larger infants (birth weight 3445.4 AE 627.2 vs. 3178.9 AE 571.2, p¼ 0.001), and greater risk of GDM-associated adverse neonatal outcomes (57.1 vs. 15.4%, p¼0.01) (Table) . Differences in neonatal outcomes were independent of BMI. By comparison, women with predominant insulin secretion deficiency had maternal characteristics similar to women with normal glucose tolerance, except for higher triglycerides (248.7 AE 73.6 vs. 189.1 AE 69, p¼0.02) and a higher risk of adverse neonatal outcomes (45.5 vs. 15.4%, p¼0.01). CONCLUSION: Heterogeneity of mechanistic processes underlying hyperglycemia exists among women with GDM. Further studies are needed to explore the impact of GDM subtypes on treatment response.
83 Prediction of adverse outcomes by metabolic biomarkers of mid-trimester maternal plasma in pregnancies with SLE to identify, counsel, and manage high risk patients. This study aims to identify discriminatory biomarkers in mid-trimester maternal blood for the prediction of adverse outcomes in patients with SLE. STUDY DESIGN: The study population consisted of pregnant women whose plasma was taken in mid-trimester and was available for metabolic profiling: (1) pregnant women with SLE and normal pregnancy outcome (Group 1, n¼21); (2) pregnant women with SLE with subsequent adverse pregnancy outcome (Group 2, n¼12); (3) normal pregnant women without SLE, matched for gestational age at sampling (Group 3, n¼10). Adverse pregnancy outcome was defined as one or more of the following: fetal death in utero, preeclampsia, small for gestational age (birth weight <5 th percentile), indicated preterm birth (<36 weeks), and neonatal death. Stored midtrimester maternal plasma was measured for sFlt-1/PlGF. Integrative profiles of primary metabolite and phospholipid were acquired using gas chromatography time-of-flight mass spectrometry (GC-TOF MS) and liquid chromatography Orbitrap mass spectrometry (LCOrbitrap MS). RESULTS: Among 33 women with SLE, adverse pregnancy outcome developed in 12 (36%). Metabolite profiling of mid-trimester maternal plasma samples identified 389 metabolites using GC-TOF MS and LC-Orbitrap MS. Partial least squares discriminant analysis (PLS-DA) showed clear discrimination among the profiles of SLE with normal pregnancy outcome, SLE with adverse pregnancy outcome, and normal pregnancy (Groups 1,2, and 3) [Fig 1] . Binary logistic regression modeling suggested potential metabolic biomarkers discriminating Group 1 and 2 to predict adverse pregnancy outcome in SLE. Receiver operating characteristic (ROC) analysis revealed the best predictability for adverse pregnancy outcomes with the linear combination of two metabolites (LPC 22:5 and tryptophan) with AUC of 0.944, comparable to the AUC of sFlt-1/PlGF (AUC 0.857) [Fig 2] . CONCLUSION: Metabolic biomarkers in mid-trimester maternal blood can accurately predict composite adverse pregnancy outcomes in patients with SLE. OBJECTIVE: Glucose tolerance testing for gestational diabetes (GDM) has poor reproducibility between tests and high variability by time of day. In contrast, metabolomic testing of serum has good reproducibility for multiple metabolites, including those altered in GDM. We hypothesize that metabolomics can identify GDM and maintain reproducibility over 3-7 days. STUDY DESIGN: Prospective observational study of women with singleton gestation undergoing GDM screening at 24-28 wks. Two fasting plasma samples were obtained 3-7 days apart. Women were excluded for major medical illness. Exposure groups were defined as glucose tolerant (GT), defined as 1-hour, 50-g glucose challenge test <120mg/dL, and GDM, defined by Carpenter Coustan criteria on a 3-hour, 100-g glucose tolerance test. We determined a priori that 35 subjects per group were needed to detect a mean difference of 1-standard deviation with an alpha of 0.01 and 90% power between GDM and GT. Aqueous extracts of plasma were analyzed by reversephase nanoLC-ESI-MS/MS on a SCIEX 5600 TripleTOF in the
